Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
1999-04-06
2001-10-09
Jarvis, William R. A. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S558000
Reexamination Certificate
active
06300374
ABSTRACT:
The present invention concerns compositions and their use in the treatment of skin disorders particularly, but not limited, to eczema, psoriasis and dermatitis, and also compositions and their use in treatment of cancer, particularly skin cancer.
Conjugated linoleic acid and linoleic acid are well-known for their therapeutic, particularly chemotherapeutic, properties (see, for example, Belury, M. A., 1995 Nutrition Reviews, 53 (4): 83-39 and references therein; Pariza, M. W., Chemistry & Industry, Jun. 16, 1997, 464-466; EP 0 087 863; EP 0 044 341; EP 0 078 434; EP 0 003 407; EP 0 057 175; EP 0 071 357; EP 0 085 579; EP 0 139 480), and have comprised non-essential components of compositions for treating skin disorders (EP 0 727 991). WO 95/13806 discloses the use of a composition comprising zinc salts of 68% (unconjugated) linoleic acid and 10% conjugated isomers of linoleic acid for use in treating skin disorders.
However, the present inventor has now found that zinc salts of conjugated linoleic acids have an unexpectedly great efficacy in the treatment of skin disorders when compared to for example unconjugated zinc linoleate.
According to the present invention, there is provided a composition for use in treating skin disorders comprising substantially the zinc salt of at least one conjugated linoleic acid. The composition may be used in a method of treating skin disorders.
Also provided is the use of a composition comprising substantially the zinc salt of at least one conjugated linoleic acid in the manufacture of a medicament for treating skin disorders.
Also provided is a method of manufacture of a medicament for treating skin disorders comprising the use of a composition comprising substantially the zinc salt of at least one conjugated linoleic acid.
Also provided is a method of treatment of a skin disorder comprising the use of a composition comprising substantially the zinc salt of at least one conjugated linoleic acid.
Methods of manufacture and use of the compositions and medicaments of the present invention will be readily apparent to one skilled in the art and are exemplified in the Examples below.
The composition may comprise at least 50%, for example at least 60%. 70%, 80% or 90%, the zinc salt of at least one conjugated linoleic acid. For example it may substantially comprise the zinc salt of a conjugated linoleic acid or it may comprise a substantially greater proportion of the zinc salt or salts of at least one conjugated linoleic acid than of zinc linoleate.
The present inventor has found that the zinc salts of conjugated linoleic acids have a surprisingly great efficacy, compared to that of conjugated linoleic acids alone (which may act as irritants) and of zinc linoleate, when used in the treatment and/or prophylaxis of skin disorders such as eczema, psoriasis, cold sores (herpes) and dermatitis.
The conjugated linoleic acids are a large family of molecules. Dienoic conjugated linoleic acids may be used as the basis of the zinc salts of the present invention. For example, 9,11-octadecadienoic acid or 10,12-octadecadienoic acid may be used. These unsaturated molecules contain double bonds and so there are a number of geometric isomes of the molecules, for example cis9,trans11-octadecadienoic acid and trans9,cis11-octadecadienoic acid.
The compositions of the present invention may be used in conjunction with a pharmaceutically acceptable carrier, diluent or excipient. Such carriers, diluents and excipients are well known—see for example Remington's Pharmaceutical Sciences and US Pharmacopoeia (1984) Mack Publishing Company, Easton, Pa.
The composition may also comprise at least one antioxidant, for example tocopherol (Vitamin E).
The composition may also comprise for example zinc linoleate and/or the zinc salt of at least one other fatty acid. Conjugated lioleic acids are usually prepared by the isomerisation of linoleic acid, and are therefore liable to contain various residues of linoleic acid. Thus zinc linoleate may be among the zinc salts formed when the isomerised linoleic acid is converted into zinc salts.
The zinc salts of conjugated linoleic acids appear to be more effective than zinc salts of other fatty acids, and (see examples B and C below) do not owe their activity to the presence of zinc alone.
Medicaments and compositions according to the present invention may be administered in doses (i.e. concentrations and quantities) sufficient to effect the desired prophylactic or therapeutic result. Such doses may be readily determined using simple dose-response experiments.
The doses may be such that they are substantially non-irritant to the patient.
According to a further aspect of the present invention, there is provided a composition for use in treating cancer comprising substantially the zinc salt of at least one conjugated linoleic acid. The composition may be used in a method of treating cancer.
Also provided is the use of a composition comprising substantially the zinc salt of at least one conjugated linoleic acid in the manufacture of a medicament for treating cancer.
Also provided is a method of manufacture of a medicament for treating cancer comprising the use of a composition comprising substantially the zinc salt of at least one conjugated linoleic acid.
Also provided is a method of treatment of a cancer comprising the use of a composition comprising substantially the zinc salt of at least one conjugated linoleic acid.
Methods of manufacture and use of the compositions and medicaments of the present invention will be readily apparent to one skilled in the art, particularly with reference to the Examples below.
The composition may comprise at least 50%, for example at least 60%. 70%, 80% or 90%, the zinc salt of at least one conjugated linoleic acid. For example it may substantially comprise the zinc salt of a conjugated linoleic acid or it may comprise a substantially greater proportion of the zinc salt or salts of at least one conjugated linoleic acid than of zinc linoleate.
A zinc salt may for example be of 9,11-octadecadienoic acid or 10,12-octadecadienoic acid.
The zinc salts of the compositions of the present invention for the treatment and/or prophylaxis of skin disorders also appear to be useful in the treatment and/or prophylaxis of cancer, particularly epidermal cancers such as skin cancer.
The medicament may additionally comprising a pharmaceutically acceptable carrier, diluent or excipient.
REFERENCES:
patent: 5792449 (1998-08-01), Bryce-Smith
patent: 6025334 (2000-02-01), Dupont et al.
patent: 9513806 (1995-05-01), None
XP-002053010, Derwent product sheet., Dec./1994.
Martha A. Belury et al; XP-002053009; “Dietary Conjugated Linoleic Acid Modulation of Phorbol Ester Skin Tumor Promotion”; Lawrence Erlbaum Associates, Inc., 1996, vol. 26, No. 2, pp. 149-157.
Peter W. Parodi; XP-002053008; “Conjugated Linoleic Acid: An Anticarcinogenic Fatty Acid Present in Milk Fat”; The Australian Journal of Dairy Technology, vol. 49—Nov. 1994, pp. 93-97.
Jarvis William R. A.
Kappa Pharmaceuticals Limited
Kim Vickie
Renner Otto Boisselle & Sklar
LandOfFree
Use of zinc salts of conjugated linoleic acid to treat skin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of zinc salts of conjugated linoleic acid to treat skin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of zinc salts of conjugated linoleic acid to treat skin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2599999